POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Important Safety Information
SEE MORE
This website is intended for healthcare providers in the US
Contact a Kyowa Kirin representative
Please provide your information below and the appropriate representative from Kyowa Kirin will get back to you as soon as possible.
* Indicates a required field
Want to stay informed?
We will send you the latest updates about POTELIGEO® (mogamulizumab-kpkc), as well as helpful information for you, your staff, and your patients.